PLRX

Pliant Therapeutics Inc

Add to Watchlist

Advanced Chart

1.365

+0.005(+0.370%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.370

Open

1.340

VWAP

1.34

Vol

248.05K

Mkt Cap

83.79M

Low

1.325

Amount

332.83K

EV/EBITDA(TTM)

Total Shares

60.33M

-191.88M

EV/OCF(TTM)

P/S(TTM)

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Its second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs targeting muscular dystrophies. It is also developing PLN-101095 an oral, dual inhibitor of αvß8 and αvß1 integrins for the treatment of solid tumors. Its clinical programs also include PLN-101325, an allosteric agonistic monoclonal antibody against α7β1 for treatment of muscular dystrophies.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.659

-28.32%

-0.482

-49.29%

-0.428

-47.85%

Estimates Revision

The market is revising Upward the revenue expectations for Pliant Therapeutics, Inc. (PLRX) for FY2025, with the revenue forecasts being adjusted by 113.89% over the past three months. During the same period, the stock price has changed by -54.19%.

Revenue Estimates for FY2025

Revise Upward

+113.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-39.6%

In Past 3 Month

Stock Price

Go Down

-54.19%

In Past 3 Month

13 Analyst Rating

284.62% Upside

Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 5.25 USD with a low forecast of 1.50 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

11 Hold

0 Sell

Hold

284.62% Upside

Current: 1.365

Low

1.50

Averages

5.25

High

17.00

284.62% Upside

Current: 1.365

Low

1.50

Averages

5.25

High

17.00

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-03-18

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-03-18

Reiterates

Hold

Reason

Needham

Joseph Stringer

Strong Buy

Hold

Downgrades

$10

2025-03-04

Reason

Needham

Joseph Stringer

Price Target

$10

2025-03-04

Downgrades

Strong Buy

Hold

Reason

Wells Fargo

Tiago Fauth

Hold

Maintains

$4 → $3

2025-03-04

Reason

Wells Fargo

Tiago Fauth

Price Target

$4 → $3

2025-03-04

Maintains

Hold

Reason

Cantor Fitzgerald

Pete Stavropoulos

Hold

Initiates

n/a

2025-03-04

Reason

Cantor Fitzgerald

Pete Stavropoulos

Price Target

n/a

2025-03-04

Initiates

Hold

Reason

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics with a Neutral rating and no price target. The company is discontinuing the Pase 2b BEACON-IPF study of bexotegrast in idiopathic pulmonary fibrosis, the analyst tells investors in a research note. The firm says that while Pliant has two additional clinical stage programs and a third Phase 1-ready asset, without clear visibility on program prioritization, it remains on the sidelines.

RBC Capital

Brian Abrahams

Hold

Maintains

$4 → $3

2025-03-04

Reason

RBC Capital

Brian Abrahams

Price Target

$4 → $3

2025-03-04

Maintains

Hold

Reason

Citigroup

David Lebowitz

Hold

Maintains

$4 → $1.5

2025-03-04

Reason

Citigroup

David Lebowitz

Price Target

$4 → $1.5

2025-03-04

Maintains

Hold

Reason

Citi lowered the firm's price target on Pliant Therapeutics to $1.50 from $4 and keeps a Neutral rating on the shares. The company reported Q4 earnings after announcing it had discontinued the Phase 2b BEACON-IPF trial for bexotegrast in idiopathic pulmonary fibrosis after an outside expert panel completed an secondary review and concurred with the Data Safety Monitoring Board's recommendation, the analyst tells investors in a research note. Post the update, Citi substantially reduce its bexotegrast estimates, delaying a timeline of potential launch and lowering its probability of success to 20% from 40%.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pliant Therapeutics Inc (PLRX.O) is -0.64, compared to its 5-year average forward P/E of -5.77. For a more detailed relative valuation and DCF analysis to assess Pliant Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.77

Current PE

-0.64

Overvalued PE

-2.71

Undervalued PE

-8.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.78

Current EV/EBITDA

1.22

Overvalued EV/EBITDA

0.19

Undervalued EV/EBITDA

-5.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

307.90

Current PS

46.59

Overvalued PS

592.80

Undervalued PS

22.99

Financials

Annual

Quarterly

FY2025Q1

0.00

Total Revenue

FY2025Q1

YoY :

+12.49%

-58.94M

Operating Profit

FY2025Q1

YoY :

+19.62%

-56.17M

Net Income after Tax

FY2025Q1

YoY :

+17.95%

-0.92

EPS - Diluted

FY2025Q1

YoY :

+54.66%

-49.13M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.5M

USD

6-9

Months

0.0

USD

0-12

Months

919.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 193.24% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

690.7K

Volume

6-9

Months

0.0

Volume

0-12

Months

267.6K

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.0M

Volume

Months

6-9

0.0

Volume

Months

0-12

669.3K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.5M

USD

6-9

Months

0.0

USD

0-12

Months

919.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

PLRX News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

17:41:04

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c)

2025-05-08

16:41:51

Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)

2025-05-01 (ET)

2025-05-01

16:56:39

Pliant Therapeutics to reduce workforce by 45%

News

4.5

05-01Newsfilter

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

7.0

04-25Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX

7.0

04-21Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

People Also Watch

ORIC

Oric Pharmaceuticals Inc

Orchid Island Capital Inc

Standard Motor Products Inc

United Fire Group Inc

Silvercorp Metals Inc

FAQ

What is Pliant Therapeutics Inc (PLRX) stock price today?

The current price of PLRX is 1.365 USD — it has increased 0.37 % in the last trading day.

PLRX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PLRX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Pliant Therapeutics Inc (PLRX) stock price today?

What is Pliant Therapeutics Inc (PLRX)'s business?

What is the price predicton of PLRX Stock?

What is Pliant Therapeutics Inc (PLRX)'s revenue for the last quarter?

What is Pliant Therapeutics Inc (PLRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pliant Therapeutics Inc (PLRX)'s fundamentals?

How many employees does Pliant Therapeutics Inc (PLRX). have?

What is Pliant Therapeutics Inc (PLRX) market cap?